MIAMI BEACH, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- AirSculpt® Technologies, Inc., (“AirSculpt”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced the opening of its newest center in San Jose, California. The new opening increases the company’s center count to 26 locations throughout the United States, Canada and the UK.
AirSculpt® is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt locations. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
“We’re excited to bring AirSculpt to San Jose,” said Todd Magazine, Chief Executive Officer at AirSculpt® Technologies. “San Jose is our second northern California location and our fifth California location overall, adding to our Sacramento, San Diego, Beverly Hills and Orange County offices. The addition of San Jose speaks to the demand for AirSculpt’s premium experience among Californians.”
The San Jose location is easily accessible from San Francisco and Oakland. The new office is located at 500 South Winchester Blvd, Suite 10 in San Jose and can be reached at (408) 889 5755.
More than 40,000 AirSculpt cases have been performed in AirSculpt’s premium locations throughout the U.S, Canada and the United Kingdom. For additional information about scheduling a virtual or in-person consultation at any of the 26 centers, visit www.airsculpt.com.
About AirSculpt®
AirSculpt® is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
Investor Contact:
Steven Halper/Caroline Paul
Managing Directors, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Stephanie Evans Greene
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.59 |
Daily Change: | -0.09 -5.36 |
Daily Volume: | 400,970 |
Market Cap: | US$92.030M |
December 17, 2024 November 08, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load